Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Microbiome company Finch raises $53M ahead of anti-infective readout

Finch's series C round is designed to carry the microbiome company through what could be a pivotal data readout next year in Clostridium difficile infection, while also allowing it to continue building on a pair of platforms that deliver bacterial cocktails to the gut.

In a round announced Thursday, Finch Therapeutics Group Inc. raised

Read the full 537 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE